Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine® TCR-T Candidate IMA203CD8 Targeting PRAME

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Related Keywords

Germany ,Houston ,Texas ,United States ,Eva Mulder ,Cedrik Britten ,Anja Heuer ,Immatic Actengine ,Instagram ,Linkedin ,Twitter ,Corporate Communications ,Trophic Communications ,Chief Medical Officer ,All Immatic ,Stem Cell Therapeutics Research Laboratory ,Adoptive Cell Therapies ,Looking Statements ,Investor Relations ,Health ,Business ,Globe Newswire ,Cancer ,Tumors ,